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Abstract
Introduction: Targeting CD74 as the invariant chain of major histocompatibility complexes (MHC) became possible
by the availability of a specific humanized monoclonal antibody, milatuzumab, which is under investigation in
patients with hematological neoplasms. CD74 has been reported to regulate chemo-attractant migration of
macrophages and dendritic cells, while the role of CD74 on peripheral naïve and memory B cells also expressing
CD74 remains unknown. Therefore, the current study addressed the influence of milatuzumab on B-cell
proliferation, chemo-attractant migration, and adhesion molecule expression.
Methods: Surface expression of CD74 on CD27- naïve and CD27+ memory B cells as well as other peripheral blood
mononuclear cells (PBMCs) obtained from normals, including the co-expression of CD44, CXCR4, and the adhesion
molecules CD62L, b7-integrin, b1-integrin and CD9 were studied after binding of milatuzumab using multicolor
flow cytometry. The influence of the antibody on B-cell proliferation and migration was analyzed in vitro in detail.
Results: In addition to monocytes, milatuzumab also specifically bound to human peripheral B cells, with a higher
intensity on CD27+ memory versus CD27- naïve B cells. The antibody reduced B-cell proliferation significantly but
moderately, induced enhanced spontaneous and CXCL12-dependent migration together with changes in the
expression of adhesion molecules, CD44, b7-integrin and CD62L, mainly of CD27- naïve B cells. This was
independent of macrophage migration-inhibitory factor as a ligand of CD74/CD44 complexes.
Conclusions: Milatuzumab leads to modestly reduced proliferation, alterations in migration, and adhesion
molecule expression preferentially of CD27- naïve B cells. It thus may be a candidate antibody for the autoimmune
disease therapy by modifying B cell functions.
Introduction
Milatuzumab is a humanized monoclonal antibody (also
called hLL1 or IMMU-115) targeting a cell surface-
expressed epitope of the molecule CD74 which is
expressed on monocytes, macrophages, and B cells but
not T cells [1]. Currently, milatuzumab is a candidate
immunotherapeutic antibody being studied in multiple
myeloma, non-Hodgkin lymphoma, and chronic
lymphocytic leukemia (CLL) [1]. B cells of these hema-
tological tumors express the target molecule, CD74, at
high levels and internalize it rapidly after milatuzumab
binding [2,3]. Consequently, growth inhibition and
induction of apoptosis in B-cell lines in the presence of
a second cross-linking antibody (for example, Fcg-speci-
fic F(ab)2 fragments to mimic the role of effector cells
or cross-linking molecules present in vivo) have been
reported [4]. Therefore, milatuzumab seems to block
CD74 signaling pathways and act as an antagonist. In
preclinical models, treatment of cynomolgus monkeys
with milatuzumab led to a decrease of peripheral blood
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mononuclear cells (PBMCs) but not to systemic toxicity
or enhanced mortality [1].
The target molecule of milatuzumab, CD74, is a trans-
membrane glycoprotein that associates with the major
histocompatibility complex (MHC) class II a and b
chains and is also known as MHC class II invariant
chain (Ii). In this context, CD74 functions as a chaper-
one molecule and is implicated in antigen presentation
[5,6]. Moreover, CD74 is involved in several signaling
pathways of B-cell survival. In particular, binding of
macrophage migration inhibitory factor (MIF), a chemo-
kine produced by a variety of cell types, including
monocytes and lymphocytes, to a receptor complex
formed by CD74 and CD44 initiates a signaling cascade
in B cells which involves spleen tyrosine kinase (Syk),
phosphatidylinositol 3-kinase (PI3K), and Akt, leading to
nuclear factor-kappa-B (NF-B) activation, transcription
of anti-apoptotic genes, and (finally) cell survival and
proliferation [7-10]. Another CD74-dependent anti-
apoptotic pathway promotes B-CLL cell growth and sur-
vival by activating p65 (a member of the NF-B family),
upregulating expression of the transactivation isoforms
of p63 (TAp63), and inducing Bcl-2 expression and
interleukin-8 (IL-8) secretion [2,11,12]. Furthermore,
CD74 has been shown to be involved in B-cell matura-
tion by activating a TAFII105-NF-B-dependent tran-
scription program [13,14]. A recently detected complex
formed by CD74 and CXCR4 acts as an alternative func-
tional MIF receptor, resulting in phosphorylation of Akt
in Jurkat cells [15]. Since CXCR4 is known as the recep-
tor involved in the migration of B cells toward CXCL12
[16,17], it is not clear to which extent this function can
be influenced by the anti-CD74 antibody, milatuzumab.
Previous studies addressing the function of milatuzu-
mab are based on B-cell lines or B cells that are from
patients with CLL and that express CD74 at high levels
or mouse splenocytes and cell lines [1,4]. In contrast,
there is a lack of knowledge about the effects of milatu-
zumab on B cells from healthy individuals or from
patients with non-malignant diseases. Therefore, the
present study analyzed the surface expression of CD74
and the related molecules, CD44 and CXCR4, as well as
the functional impact of milatuzumab on B cells from
healthy donors, including B-cell proliferation and migra-
tion toward CXCL12. Furthermore, the influence of
milatuzumab on the co-expression of b1-integrin, CD9,
b7-integrin, and CD62L involved in cell adhesion was
investigated.
Materials and methods
Subjects and cell preparation
Peripheral blood from 32 healthy Caucasian individuals
(24 females and 8 males) with a mean age of 34 years
(range of 19 to 66 years) was collected after informed
consent was obtained and approval was granted by the
ethics committee of the Charité University Medicine
Berlin. PBMCs from some individuals were used for dif-
ferent experiments on different days. PBMCs were pre-
pared by density gradient centrifugation by using Ficoll-
Paque Plus (GE Healthcare Bio-Sciences AB, Uppsala,
Sweden), as reported previously [18]. Washing steps
were performed depending on further processing with
cold phosphate-buffered saline (PBS)/0.2% bovine serum
albumin (BSA) (for direct cell staining), PBS (for prolif-
eration experiments), or pre-warmed RPMI 1640 med-
ium supplemented with 0.5% BSA (assay medium for
transwell migration assays and incubation experiments).
Cells were stained for flow cytometric analyses immedi-
ately or after in vitro experiments.
Flow cytometry
PBMCs were incubated at 4°C for 15 minutes with the
following fluorochrome-labeled anti-human monoclo-
nal antibodies in PBS/0.2% BSA: anti-CD19-phycoery-
thrin-Cy7 (PE-Cy7, clone SJ25C1; BD Biosciences, San
Jose, CA, USA), anti-CD3-Pacific Blue (PacB, clone
UCHT1; BD Biosciences), anti-CD14-PacB (clone
M5E2; BD Biosciences), anti-CD27-Cy5 (clone 2E4,
kind gift from René van Lier, Academic Medical Cen-
ter, University of Amsterdam, The Netherlands), anti-
CD74-FITC (clone M-B741; BD Biosciences), milatuzu-
mab-PE (hLL1; Immunomedics, Inc., Morris Plains, NJ,
USA, labeled in-house at the Deutsches Rheuma-
forschungszentrum), anti-CD44-FITC (clone L178; BD
Biosciences), anti-CXCR4-PE (clone 12G5; BD Bios-
ciences), anti-b1-integrin-PE (clone MAR4; BD Bios-
ciences), anti-CD62L-FITC (clone 145/15; Miltenyi
Biotec GmbH, Bergisch Gladbach, Germany), and anti-
CD9-FITC (clone MM2/57; Chemicon, Schwalbach,
Germany). Rat anti-mouse anti-b7-integrin-PE (clone
FIB504; BD Biosciences), which cross-reacts with
human b7-integrin, was used to detect human b7-
integrin, as described before [19-21]. Specificity of
staining was confirmed by corresponding isotype con-
trols or blocking by using unconjugated milatuzumab
(20-fold concentration). Pre-incubation of PBMCs with
unconjugated milatuzumab for 15 minutes on ice did
not have an impact on the staining and detection with
anti-CD62L-FITC, anti-CD44-FITC, and anti-b7-integ-
rin-PE, so potential sterical interference could be lar-
gely excluded.
DAPI (4,6 diamidino-2-phenylindole) (Molecular
Probes, now part of Invitrogen Corporation, Carlsbad,
CA, USA) was added immediately before cytometric
analysis to determine or exclude dead cells. Flow cyto-
metric data were acquired by using a FACSCanto II ana-
lyzer (BD Biosciences) and analyzed by using FCS
Express 3.0 (De Novo Software, Thornhill, ON, Canada).
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CD19-/CD3+/SSClow T cells, CD19-/CD14+/SSChigh
monocytes, and CD19+/CD3-/CD14- B cells were ana-
lyzed for CD74 expression and milatuzumab binding.
CD19+/CD3-/CD14-/CD27- naïve B cells and CD19
+/CD3-/CD14-/CD27+ memory B cells were also ana-
lyzed for expression of CD44 and CXCR4.
Proliferation experiments and determination of
macrophage migration inhibitory factor concentrations
For proliferation experiments, PBMCs were labeled with
carboxyfluorescein succinimidyl ester (CFSE) in accor-
dance with the instructions of the manufacturer (Mole-
cular Probes/Invitrogen Corporation). In 96-well plates
(U-bottom; Greiner Bio-One GmbH, Frickenhausen,
Germany), approximately 1 × 106 PBMCs in 250 μL of
pre-warmed RPMI 1640 medium, supplemented with
fetal calf serum (10%; Invitrogen, Darmstadt, Germany)
and penicillin/streptomycin (1 U/mL; Sigma-Aldrich
Chemie GmbH, Munich, Germany) with or without
unconjugated milatuzumab (end concentration of 10 μg/
mL; Immunomedics, Inc.) or as control with intravenous
immunoglobulin (IVIG) (end concentration of 10 μg/
mL; Octapharma AG, Lachen, Switzerland) were stimu-
lated with IL-2 (end concentration of 20 ng/mL; R&D
Systems, Minneapolis, MN, USA), IL-10 (end concentra-
tion of 20 ng/mL; R&D Systems), and CpG 2006 (end
concentration of 0.3 nmol/mL; TIB Molbiol GmbH, Ber-
lin, Germany) in the presence of cross-linking F(ab)2
(end concentration of 2 μg/mL; Dianova, Hamburg, Ger-
many) for 7 days at 37°C in 5% CO2. Thereafter, the
plates were centrifuged and the supernatants were col-
lected and stored at -20°C for later determination of
MIF concentrations. The cells were washed with PBS/
0.2% BSA and stained for subsequent cytometric ana-
lyses. CD19+/CD3 -/CD14- B cells were analyzed for
their proliferation by using CFSE labeling.
MIF concentrations in the supernatants, naturally pro-
duced by the cultured PBMCs, were determined with a
quantitative sandwich enzyme immunoassay in accor-
dance with the instructions of the manufacturer (R&D
Systems). Optical density was measured by using an
Anthos HTII microplate reader (450 and 578 nm;
Anthos Labtec Instruments GmbH, Wals, Austria). MIF
concentrations were calculated by using an MIF stan-
dard solution.
Transwell migration assays
Migration assays with PBMCs were performed by using
24-well plates with transwell inserts (diameter of 6.5
mm and pore size of 5 μm; Corning Life Sciences,
Acton, MA, USA) coated with fibronectin, as described
previously [22]. The lower chamber contained 600 μL of
assay medium supplemented with CXCL12 (end concen-
tration of 50 nM; R&D Systems), and baseline migration
was defined as spontaneous migration in the absence of
chemokine. The upper chamber contained 1 to 2 × 106
PBMCs in 100 μL of assay medium with or without
unconjugated milatuzumab (hLL1, end concentration 10
μg/mL), and human IgG1 (end concentration of 10 μg/
mL; Sigma-Aldrich Chemie GmbH) or IVIG (end con-
centration of 10 μg/mL) served as a control. After 90
minutes of incubation at 37°C in a humid 5% CO2
atmosphere, non-migrated cells (upper chamber) and
migrated cells (lower chamber) were collected, washed
with PBS/0.2% BSA, and stained for cytometric analyses.
CD19+/CD3-/CD14-/CD27-/+ B cells were enumerated,
and frequencies of migrated cells were calculated with
this formula: [migrated cells/(migrated + non-migrated
cells)] × 100.
Incubation experiments
For incubation experiments, 24-well plates with flat-bot-
tom wells (Greiner Bio-One GmbH) containing an aver-
age of 2 × 106 PBMCs in 1 mL of assay medium with or
without unconjugated milatuzumab (end concentration
of 10 μg/mL) or IgG1 (end concentration of 10 μg/mL)
or IVIG (end concentration of 10 μg/mL) as controls
were incubated for 90 minutes at 37°C in 5% CO2.
Thereafter, cells were collected, washed with PBS/0.2%
BSA, and stained for cytometric analyses. CD19+/CD3-/
CD14 -/CD27-/+ B cells were analyzed for the expression
of CD44, CXCR4, b1-integrin, CD9, b7-integrin, and
CD62L.
Statistical analyses
GraphPad Prism version 4 for Windows (GraphPad
Software, San Diego, CA, USA) was used for statistical
analyses. Wilcoxon tests were performed to compare
different experimental conditions or cell populations
within one individual (paired data). P values of not
more than 0.05 (which were considered significantly dif-
ferent), of not more than 0.01, and of not more than
0.001 are indicated by a single, double, and triple aster-
isk, respectively, in Figures 1, 2, 3 and 4.
Results
Distinct surface expression of CD74, CD44, and CXCR4 on
CD19+/CD27- naïve versus CD19+/CD27+ memory B cells
Initially, direct labeling of PBMCs was performed to
determine the surface expression of CD74 on B cells, T
cells, and monocytes (Figure 1A). The surface expres-
sion of CD44 and CXCR4, molecules reported to be
associated with CD74 expression, was also analyzed on
human CD27- naïve and CD27+ memory B-cell subpo-
pulations (Figure 1B).
With a commercial anti-CD74 antibody used as a con-
trol, T cells did not express CD74 - geometric mean
fluorescence intensity (MFI) of 2.9 ± 0.5, mean ±
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Figure 1 Surface expression of CD74, CD44, and CXCR4 on T cells, monocytes, and B cells. (A) Detection of CD74 with a commercially
available FITC-labeled anti-CD74 antibody (n = 8) and PE-labeled milatuzumab (n = 9) on T cells, monocytes, and B cells. For each staining,
representative histograms, including an isotype control or blocking experiment, are shown. Competitive blocking experiments were performed
by using unlabeled milatuzumab (20-fold concentration). Significant differences were observed between the CD74 expression levels of T cells,
monocytes, and B cells (Wilcoxon test), and specificity of the staining was confirmed. (B) Detection of CD74 (n = 10), CD44 (n = 8), and CXCR4
(n = 12) on CD27- naïve and CD27+ memory B cells. These surface molecules showed a distinct expression profile between these B-cell
subpopulations (Wilcoxon test). **P ≤ 0.01; ***P ≤ 0.001. BD, BD Biosciences; FITC, fluorescein isothiocyanate; MFI, (geometric) mean fluorescence
intensity; PE, phycoerythrin.
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standard deviation (SD) - whereas monocytes (MFI of
23.7 ± 7.1) and B cells (MFI of 44.3 ± 13.6) expressed
this molecule at significantly higher levels. The specifi-
city of CD74 staining was confirmed by isotype controls,
and the same binding characteristics were confirmed by
using fluorescence-labeled milatuzumab. When the MFI
was analyzed, milatuzumab did not bind to T cells (MFI
of 9.6 ± 1.3) but showed substantial binding to mono-
cytes (MFI of 304 ± 70) and B cells (MFI of 704 ± 175).
To confirm the specificity of this binding, unconjugated
milatuzumab was added to the staining. Both anti-CD74
antibodies competed for the same epitopes, so the more
concentrated unconjugated milatuzumab prevented
binding of conjugated milatuzumab. This blocking was
seen only partially on monocytes but completely on B
cells analyzed in all further experiments. Therefore,
milatuzumab binding to B cells appeared to be highly
specific among PBMCs.
Almost all peripheral blood B cells expressed CD74
and were recognized by milatuzumab. In detail, milatu-
zumab binding was detected on 98.3% ± 1.2% of CD27-
naïve and 97.0% ± 2.4% of CD27+ memory B cells (data
not shown), but for each individual analyzed, the MFI of
CD74 binding on CD27+ memory B cells was higher
than those on CD27- naïve B cells (by an average of 1.3-















































































Figure 2 Effects on proliferation of CD19+ B cells and macrophage migration inhibitory factor (MIF) concentration in vitro by
milatuzumab. (A) Frequency of proliferated CD19+/CD3 -/CD14- B cells according to their carboxyfluorescein succinimidyl ester (CFSE)
fluorescence intensity. CFSE-labeled peripheral blood mononuclear cells were cultured for 7 days with or without milatuzumab or intravenous
immunoglobulin (IVIG) at 37°C in 5% CO2 and simultaneously stimulated with IL-2, IL-10, F(ab)2, and CpG (n = 6). Addition of milatuzumab as
well as IVIG resulted in a modest, but significant, inhibition of the proliferation (Wilcoxon test). For each condition, a representative histogram is
shown. (B) The concentration of the chemokine MIF as a potential ligand of CD74 was tested in cell culture supernatants (n = 7), as described
above, and showed no significant differences between the conditions (Wilcoxon test). (C) Proportion of dead CD19+ B cells, identified as high
positive staining with DAPI (n = 3). There was no substantial influence observed by either IVIG or milatuzumab (Wilcoxon test). *P ≤ 0.05. CpG,
cytosine-phosphatidyl-guanosine; DAPI, 4,6 diamidino-2-phenylindole; F(ab)2, protein of two antigen-binding fragments; IL, interleukin; ns, not
significant.
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co-receptor of CD74, CD44, was identified on almost all
B cells (96.7% ± 2.0% of CD27- naïve and 99.3% ± 0.9%
of CD27+ memory B cells; data not shown), whereas the
density of CD44 expression (MFI) on CD27+ B cells was
significantly higher than that on CD27- B cells (by an
average of twofold; P = 0.0078). In contrast, only 82.2%
± 6.6% of CD27+ B cells expressed CXCR4, whereas
98.0% ± 1.1% of CD27- B cells expressed this molecule
(data not shown). Accordingly, the MFI of CXCR4 on
CD27- naïve B cells was significantly higher (by an aver-
age of 3.1-fold; P = 0.0005) than the MFI of CD27+
memory B cells. It should be noted that no correlation
was observed between the individual expression levels of
CD74, CXCR4, and CD44.
effective CXCL12-dependent migration
(baseline migration subtracted)













































Figure 3 Influence of milatuzumab on the migration characteristics of CD19+ B cells and subsets in vitro. (A) Spontaneous baseline
migration of B cells in a transwell migration assay. Peripheral blood mononuclear cells were incubated for 90 minutes at 37°C in 5% CO2 with or
without milatuzumab (n = 8) or IgG1/IVIG (n = 6) and allowed to migrate without any chemokine added. Percentages of migrated cells are
shown. Migration was significantly enhanced (Wilcoxon test) by milatuzumab in CD19+ B cells, especially in CD27- naïve B cells. (B) Effective
CXCL12-dependent net migration determined for each individual by subtraction of the baseline migration - see (A) - from the total migration
toward CXCL12 (not shown). A significant enhancement of the migration of CD19+ B cells, especially of CD27- B cells by milatuzumab, was
identified (Wilcoxon test). In control experiments, IgG1/IVIG had no influence on migration. *P ≤ 0.05; **P ≤ 0.01. CXCL, CXC motif ligand; IVIG,
intravenous immunoglobulin; ns, not significant.
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Figure 4 Surface expression of CD44, b7-integrin, and CD62L on CD19+ B cells was preferentially reduced by milatuzumab on CD27-
naïve B cells. (A) Surface expression of CD44 after incubation of peripheral blood mononuclear cells for 90 minutes at 37°C in 5% CO2 with or
without milatuzumab (n = 7) or IgG1/IVIG (n = 7). Milatuzumab led to a significant reduction of the expression of CD44 on CD19+ B cells,
especially on CD27- naïve B cells (Wilcoxon test). (B) Expression of b7-integrin was significantly reduced (Wilcoxon test) on CD19+ B cells, mainly
confined to CD27- naïve B cells after milatuzumab incubation (n = 8), but not influenced by IgG1/IVIG (n = 7). (C) Milatuzumab (n = 9)
significantly reduced the expression of CD62L (Wilcoxon test) on CD19+ B cells, especially on CD27- naïve B cells, whereas IgG1/IVIG (n = 8) did
not modify this expression. The expression of the surface molecules CD44, b7-integrin, and CD62L on CD27+ memory B cells was not influenced
by milatuzumab. *P ≤ 0.05; **P ≤ 0.01. IVIG, intravenous immunoglobulin; ns, not significant.
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Milatuzumab moderately inhibits in vitro proliferation of
CD19+ B cells
CD74, as the invariant chain of the MHC class II mole-
cule, has been implicated in B-cell activation, as well as
survival, with the chemokine MIF as the known ligand
of CD74/CD44 complexes [1,3]. To investigate the effect
of milatuzumab on the proliferation of CD19+ B cells,
CFSE-labeled PBMCs were stimulated in vitro with IL-2,
IL-10, F(ab)2, and CpG, and cultured for 7 days with or
without unconjugated milatuzumab and with IVIG as a
control. The percentage of proliferating B cells was
determined (Figure 2A); simultaneously, the concentra-
tion of endogenously produced MIF - a ligand of CD74
produced by the cultured PBMCs and potential con-
founding factor of this experimental setting - in the
supernatants was quantified (Figure 2B).
Almost all CD19+ B cells (98.1% ± 0.6%, mean ± SD)
proliferated upon culturing PBMCs in the absence of
milatuzumab or IVIG. In comparison with this baseline
proliferation rate as well as with IVIG control (96.3% ±
1.2%), the presence of milatuzumab decreased the pro-
portion of proliferating CFSEreduced B cells modestly in
all samples (93.7% ± 3.5%; P < 0.01). In contrast, neither
milatuzumab nor IVIG had any influence on the con-
centration of MIF in the supernatants analyzed (Figure
2B). Thus, the effects observed on B-cell proliferation
were not caused by modified MIF production in the
respective cultures. Notably, the proportion of dead
CD19+ B cells, identified as high positive staining with
DAPI, was not altered by milatuzumab (19.3% ± 3.8%)
or IVIG (20.7% ± 4.3%) in comparison with control cells
not exposed to either one (21.2% ± 5.0%) (Figure 2C).
Thus, CD74 targeting by milatuzumab inhibits B-cell
proliferation to a moderate, but higher, degree in com-
parison with controls.
Anti-CD74 targeting changes the migration properties of
CD19+ B cells, especially of CD19+/CD27- naïve B cells in
vitro
The impact of CD74 targeting on B-cell in vitro migra-
tion and expression of adhesion molecules possibly
changing B-cell trafficking also was evaluated. Transwell
migration assays were used to determine the effect of
milatuzumab on the migration of B cells toward the
chemokine CXCL12 (ligand of CXCR4). Therefore,
PBMCs were incubated with or without unconjugated
milatuzumab or control IgG1/IVIG, and the migration
of B cells through a fibronectin-coated transwell insert
was assessed. Within these experiments, chemokine-
independent baseline migration and CXCL12-dependent
migration were quantified. Effective CXCL12-dependent
migration of B cells was determined by subtracting indi-
vidual baseline migration for each condition from the
total migration toward CXCL12. The frequencies of
migrated CD19+ B cells and their CD27- naïve and
CD27+ memory subpopulations are summarized in Fig-
ure 3A (baseline migration) and Figure 3B (net migra-
tion as the difference of actual minus baseline
migration). Baseline migration of CD19+ B cells (without
CXCL12 in the lower chamber) was enhanced by mila-
tuzumab from 2.7% ± 2.3% (mean ± SD) to 7.3% ± 3.4%
(CD27- B cells: 2.1% ± 1.8% to 7.0% ± 3.2%; CD27+ B
cells: 4.0% ± 3.8% to 8.0% ± 4.3%), which is consistent
with recent observations of increased spontaneous che-
mokinesis of CD74-/- macrophages [23], whereas IgG1
or IVIG did not influence baseline migration.
As noted above, CXCR4 has been reported as a co-
receptor of CD74 and is the receptor of CXCL12 [15].
Therefore, subsequent studies addressed whether mila-
tuzumab can impair CXCL12-dependent chemokinesis.
When the net CXCL12-dependent migration was used,
milatuzumab increased the frequency of migrated CD19
+ B cells significantly (P = 0.0078) from 15.8% ± 4.3% to
21.7% ± 6.6% (mean ± SD). In particular, the frequency
of migrated CD27- naïve B cells was substantially
enhanced from 14.6% ± 5.4% to 22.9% ± 7.5% (P =
0.0078), whereas CD27+ memory B cells showed no
such increase in migration (18.2% ± 6.2% to 20.4% ±
6.7%; P = 0.1953). In other words, milatuzumab
increased effective CXCL12-dependent migration of
CD19+ B cells 1.4-fold, of CD27- naïve B cells 1.6-fold,
and of CD27+ memory B cells 1.1-fold. Since the expres-
sion of CD74 on CD27+ memory was higher than on
CD27- naïve B cells, the capacity of the antibody to alter
CXCL12-dependent migration appeared to be indepen-
dent of or inversely proportional to the quantitative sur-
face expression of CD74.
Milatuzumab changes the surface expression of the
adhesion molecules CD44, b7-integrin, and CD62L,
especially on CD19+/CD27- cells in vitro
To further delineate the effects of the anti-CD74 anti-
body on B cells in addition to moderately (but signifi-
cantly) decreased proliferation and enhanced migration,
its influence on the surface expression of several mole-
cules was investigated. The MFIs and percentages of the
co-receptors CD44, CXCR4, and CD9 on B cells, as well
as the adhesion molecules b1-integrin, b7-integrin, and
CD62L involved in lymphocyte trafficking, were deter-
mined after binding of the CD74 antibody.
Incubation with unconjugated milatuzumab altered
the frequency of expression of the adhesion molecule
CD44 on total CD19+ B cells significantly, from 98.6% ±
0.6% to 97.4% ± 1.1% (mean ± SD; P = 0.0156) (Figure
4A). CD27- naïve B cells, especially, expressed signifi-
cantly less CD44 after incubation with milatuzumab
(98.3% ± 0.7% to 96.9% ± 1.2%; P = 0.0156), whereas
expression on CD27+ memory B cells was unchanged
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(99.6% ± 0.5% to 99.5% ± 0.6%). However, analyses of
respective MFIs showed that milatuzumab diminished
the MFI of CD44 staining on CD19+ B cells by an aver-
age of 10.7% (109.9 ± 20.1 to 98.0 ± 20.0) and the MFI
of CD27- naïve B cells by 12.1% (94.6 ± 15.2 to 83.2 ±
15.3), whereas the MFI of CD27+ memory B cells
showed only a modest decline of 5.3% (181.1 ± 34.0 to
172.2 ± 37.0). Overall, the expression level of CD74 and
the reduction of CD44 expression after exposure to
milatuzumab appeared to be independent or negatively
correlated.
Additionally, the expression of b7-integrin and CD62L
implicated in B-cell recirculation and tissue immigration
was analyzed with regard to potential effects by milatu-
zumab. Whereas 71.1% ± 9.1% of CD19+ B cells incu-
bated without milatuzumab expressed b7-integrin (MFI
of 73.2 ± 34.8), only 61.4% ± 8.3% of these cells
expressed this adhesion molecule after milatuzumab
incubation (P = 0.0078, MFI of 55.1 ± 22.6). The expres-
sion of b7-integrin on CD27- naïve B cells was signifi-
cantly reduced by milatuzumab (81.0% ± 8.7% compared
with 71.3% ± 7.9%, P = 0.0391, MFI of 89.1 ± 37.2 com-
pared with 63.7 ± 23.1) in contrast to CD27+ memory B
cells (49.8% ± 11.8% to 47.0% ± 9.0%, P = 0.1953, MFI
of 53.6 ± 32.1 to 46.2 ± 23.4) (Figure 4B).
Furthermore, the expression of CD62L considered to
be involved in systemic activation of B cells was dimin-
ished on CD19+ B cells by milatuzumab (from 66.1% ±
11.1% to 53.2% ± 11.6%, P = 0.0039, MFI of 30.7 ± 13.0
to 16.9 ± 8.1), mainly by reduced expression on CD27-
B cells (69.6% ± 12.9% to 54.2% ± 12.9%, P = 0.0039,
MFI of 33.2 ± 14.0 to 15.8 ± 8.3), but to a lesser extent
on CD27+ B cells (63.8% ± 14.6% to 57.0% ± 16.6%, P =
0.0547, MFI of 31.0 ± 19.4 to 22.9 ± 14.1) (Figure 4C).
Milatuzumab had no effect on the expression of
CXCR4, b1-integrin, and CD9 in regard to either the
percentage of expressing cells or the MFI values (data
not shown). Here, b1-integrin and CD9 were expressed
at higher levels on CD27+ memory B cells and CXCR4
was expressed at lower levels in comparison with CD27-
naïve B cells, respectively. Incubation with IgG1 or IVIG
also had no influence on B-cell surface expression or
MFI values of any tested molecules. Additionally, the
proportion of dead CD19+ B cells, identified as high
positive staining with DAPI, was not altered by milatu-
zumab or IgG1/IVIG in this experimental system.
Discussion
This study identified, for the first time, a number of
characteristics induced by targeting CD74 by using a
humanized anti-CD74 antibody on human peripheral B-
cell subsets. The data show a number of effects, includ-
ing modest inhibition of proliferation, enhanced sponta-
neous migration, alterations of adhesion molecule
expression, and CXCL12-dependent chemotaxis of B
cells. Since it is well documented that CXCR4/CXCL12
is important for recruitment of lymphocytes, the present
study suggests that treatment with milatuzumab might
in fact deteriorate the recruitment of B cells to the sites
of autoimmune inflammation or other involved organs
or both.
Whereas binding of milatuzumab to human B cells
and monocytes was detected, T cells did not show any
binding. Notably, significantly enhanced migration
toward CXCL12 and altered expression of the adhesion
molecules, CD44, b7-integrin, and CD62L, were found,
especially within CD19+/CD27- naïve B cells but to a
lesser extent on CD19+/CD27+ memory B cells, which
expressed CD74 at higher levels. Thus, there seems to
be an inverse correlation between CD74 expression
intensity and the effects observed after milatuzumab
binding, suggesting that distinct intracellular pathways
are induced in naïve versus memory B cells. Given the
expression of CD74 on monocytes/macrophages and B
cells, treatment with milatuzumab may permit combined
targeting of the innate and adaptive immune systems
and thus may be promising for treating autoimmunity,
as exemplified by successful anti-cytokine treatment.
Distinct surface expression of CD74 between CD19
+/CD27- naïve versus CD19+/CD27+ memory B cells
CD74 expression was detected on monocytes and B cells
(Figure 1A), consistent with previous reports [1], and
entailed a study on its effects on B cells. The binding of
milatuzumab to monocytes could be partially blocked
with unconjugated milatuzumab as well as FcR-blocking
reagents. However, the binding of milatuzumab on B
cells was blocked completely and confirmed its specifi-
city. Notably, it was identified that CD74 binding inten-
sity was lower on CD27- naïve versus CD27+ memory
cells. This observation led to the hypothesis that milatu-
zumab may have distinct effects on these B-cell subsets
and hence they were analyzed separately. It was recently
reported that CD74, together with CD44, is upregulated
in the kidney and hippocampi of diseased lupus-prone
mice and was reduced by treatment with the tolerogenic
peptide hCDR1 [24]. These data, together with the pre-
sent results, suggest that CD74 may be a suitable target
for treating autoimmune diseases, but further in vitro
data on monocytes are required.
Milatuzumab inhibits the proliferation of CD19+ B cells in
vitro and changes the expression of CD44 on CD19
+/CD27- B cells
A potential function of CD74 is regulation of B-cell acti-
vation on the basis of its implications in MHC class II
presentation. Therefore, the percentage of proliferating
cells stimulated with CpG, IL-2, F(ab)2, and IL-10 in the
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presence of milatuzumab was studied. As a result, a
modest decrease of proliferation induced by milatuzu-
mab by using CFSE labeling could be detected. This is
consistent with other studies applying this antibody and
analyzing proliferation and survival of malignant B cells
by using [3H]-thymidine uptake assays [2,4]. However,
the use of CFSE in our experiments permitted a clearer
quantification of proliferation. In addition, higher CD74
expression by B-cell malignancies does not allow a com-
parison with non-malignant cells having a lower baseline
CD74 expression, although in both cases reduced prolif-
eration could be observed after CD74 ligation. In this
regard, another study using an activating anti-CD74
antibody showed enhanced proliferation of mouse sple-
nocytes [7]. Recently, it was reported that the cytokine
midkine and its receptor-type tyrosine phosphatase ζ
(RPTPζ) are important regulators of B-cell survival.
Since this phosphatase is part of an MIF/CD74-induced
survival cascade [25], an interaction with CD74 ligation
might be possible. The present study, however, suggests
that targeting CD74 can partially inhibit proliferation of
normal human B cells, but further studies, including the
demonstration of its relevance and net effect in vivo, are
necessary.
The surface expression of CD44 known as a co-recep-
tor of CD74 has also been analyzed in CD27- naïve and
CD27+ memory B-cell subsets. Notably, CD44 was
expressed at higher levels on CD27+ memory B cells
than on CD27- naïve B cells. Thus, higher CD74 and
CD44 expressions mark CD27+ memory B cells com-
pared with CD27- naïve B cells and differ from those of
malignant lymphoma B cells overexpressing CD74
[1,26]. Milatuzumab decreased the expression of CD44,
a molecule also known to be involved in homing to lym-
phoid tissues [27], on CD27- naïve B cells but not on
CD27+ memory B cells (Figure 4A). This effect appeared
to be a possible consequence of a distinct regulation
due to the blocking of CD74. In this context, studies in
CD74-deficient mice [28] showed that a greater number
of activated dendritic cells migrated in the lymph nodes.
Consistent with that, a decrease of PBMCs in the blood
of cynomolgus monkeys treated with milatuzumab was
reported [1]. All of these data are consistent with effects
on the redistribution of immune cells under blockade of
CD74 but require confirmation by detailed in vivo
human studies.
An important aspect of the proliferation studies was to
evaluate the extent to which the chemokine MIF, as a
potential ligand of the receptor complex formed by
CD74 and CD44, could have influenced the results of
the proliferation studies. Because the MIF concentration
was not changed after milatuzumab incubation in cul-
tures over the course of 7 days, it appears unlikely that
MIF production by co-cultured PBMCs was a
confounding factor for any of the effects induced by
milatuzumab on B cells. These data are very consistent
with a recent report on macrophage function in vivo
and in vitro; using CD74-/- and MIF-/- mice, the report
demonstrated that MIF and CD74 mediate their effects
via common and independent mechanisms [23].
Milatuzumab changes migration and expression of
adhesion molecules b7-integrin and CD62L mainly of
CD19+/CD27- naïve B cells
It has been reported that CD74 targeting can lead to
changes in macrophage [23] as well as dendritic cell
migration [28], and possibly changes of adhesion also
may contribute to these effects. In the present study,
analysis of the expression of CXCR4, a molecule known
to be involved in the migration of B cells toward
CXCL12 [16,17] and able to form a complex with CD74
[15], yielded a higher expression on CD27- naïve B cells
in comparison with CD27+ memory B cells. This is con-
sistent with previous data [17,29] and suggests different
migration properties and effects on B-cell trafficking by
targeting CD74. Indeed, milatuzumab enhanced migra-
tion of CD27- naïve, but not those of CD27+ memory, B
cells without alteration of CXCR4 expression, indicating
that its surface expression does not necessarily correlate
with its migrational capacity [17,30-32]. These findings
suggest that blocking of CD74 in the CD74-CXCR4
complexes increases the amount of ‘functionally free’
CXCR4 for migration or modulation of intracellular sig-
naling pathways. In this context, it was recently sug-
gested that MIF-mediated activation of the c-Jun N-
terminal kinase (JNK) signaling pathway is dependent
on CD74 and CXCR4 in T cells and fibroblasts. In
CD74-deficient mouse embryonic fibroblasts, diminished
JNK activation was observed after MIF stimulation. Pre-
incubation with a neutralizing monoclonal anti-CXCR4
antibody completely blocked the upregulation of JNK
phosphorylation after MIF exposure in Jurkat T cells
[33]. Although such data are not available for B cells, it
is conceivable that milatuzumab targeting CD74 could
also interfere with this signaling pathway.
Of note, there was enhanced spontaneous migration
after binding of milatuzumab in the absence of any che-
mokine, and this is very consistent with macrophage
and dendritic cell data indicating that CD74 has antago-
nistic effects on cell migration. CD74-deficient dendritic
cells [28] and CD74-/- macrophages [23] have been
shown to migrate faster than wild-type cells, whereas an
activating anti-CD74 antibody has been reported to
induce a dose-dependent inhibition of in vitro migration
of mesenchymal stem cells [34]. The present study
extends the role of CD74 in migration to B cells,
whereas an inverse relationship also seems to be appar-
ent. In this regard, the observed increase of migration of
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CD19+ B cells by adding milatuzumab appears to be
involved in adherence to high endothelial venules
(HEVs) within mucosal tissue [35]. Therefore, milatuzu-
mab seems to alter cell migration that is possibly depen-
dent on the cell type and related to changes of
intracellular signaling pathways. In this context, an
enhanced migration does not necessarily imply increased
migration into lymphoid organs provided that the extent
to which this coincides with qualitative differences in
migration is not clear.
The anti-CD74 antibody was also able to decrease the
surface expression of b7-integrin as well as CD62L,
mainly on CD27- naïve B cells in vitro. b7-integrin, an
adhesion molecule binding to MadCAM-1 in coopera-
tion with a4-integrin, is known to be involved in adher-
ence to HEVs within mucosal tissues [35]. Thus, the
reduced expression induced by milatuzumab in vivo
may impair cell migration and prevent their proper par-
ticipation in immune responses. The changes of the
expression of CD62L may change the attachment of leu-
kocytes to HEVs of peripheral lymph nodes, mucosal
lymph nodes, Peyer’s patches, and the spleen [36]. Nota-
bly, expression of two fibronectin-binding molecules
[37,38], b1-integrin and CD9, was not changed by mila-
tuzumab (data not shown), so the changes observed for
CD62L and b7-integrin were not the result of a non-
specific downregulation of surface receptors but were
likely under the control of intracellular signaling path-
ways. In this context, it was recently suggested that
treatment with a tolerogenic peptide resulted in reduced
CD74 and CD44 expression [24] and may lead, via NF-
B-dependent signaling, to reduced CD69 expression
and, consequently, to reduced anti-double-stranded
DNA autoantibody production in a lupus mouse model.
Another study [7] found that intramembraneous clea-
vage after CD74/MIF binding leads to NF-B activation
via the Syk/Akt phosphorylation pathway. However,
intracellular signaling downstream of CD74 appears to
be very complex and may differ if MIF, CD44, or
CXCR4 is involved. Therefore, the complex signaling
pathways of CD74 in B cells require comprehensive stu-
dies that consider the context.
Since the effects of milatuzumab on adhesion mole-
cule expression and migration were observed for CD27-
naïve B cells, it is likely that their impaired trafficking
leads to the prevention of ongoing immune memory
induction and thereby could lead to successful immune
intervention. Further studies, including in vivo data that
also take into account the complex interaction with
other immune and non-immune cells expressing CD74
and targeted by milatuzumab, are needed to fully deline-
ate the potential of anti-CD74 therapy in autoimmune
diseases. Milatuzumab has a different mechanism of
action than that of the B cell-depleting anti-CD20 anti-
body, rituximab. Thus, milatuzumab may be an alterna-
tive treatment of systemic lupus erythematosus or other
autoimmune diseases, offering a co-targeting of mono-
cytes/macrophages and B cells.
Conclusions
Milatuzumab leads in vitro to modestly reduced prolif-
eration, to alterations in migration, and to adhesion
molecule expression preferentially of CD27- naïve B
cells. By targeting and consequently modifying functions
of B cells and, potentially, monocytes/macrophages, it
may change important migrational functions and thus
may be a promising candidate antibody for treatment of
autoimmune diseases.
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